Compare · PACB vs WAT
PACB vs WAT
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PACB and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $35.87B, about 79.7x PACB ($450.4M).
- Over the past year, PACB is up 19.4% and WAT is up 4.8% - PACB leads by 14.6 points.
- PACB has been more active in the news (14 items in the past 4 weeks vs 8 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 24 for PACB).
- Company
- Pacific Biosciences of California Inc.
- Waters Corporation
- Price
- $1.45-10.80%
- $365.34-2.95%
- Market cap
- $450.4M
- $35.87B
- 1M return
- -15.99%
- +4.48%
- 1Y return
- +19.42%
- +4.79%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- 1995
- News (4w)
- 14
- 8
- Recent ratings
- 24
- 25
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest PACB
- SEC Form 4 filed by Director Mohr Marshall
- SEC Form 4 filed by Director Gibson Christopher
- SEC Form 4 filed by Director Smith Christopher M
- SEC Form 4 filed by Director Valantine Hannah
- SEC Form 4 filed by Director Livingston Randall S
- SEC Form 4 filed by Director Ericson William W.
- SEC Form 4 filed by Director Milligan John F
- SEC Form 4 filed by Director Ordonez Kathy
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Pacific Biosciences of California Inc.
Latest WAT
- Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
- Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
- Wolfe Research resumed coverage on Waters with a new price target
- Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
- Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
- SEC Form SD filed by Waters Corporation
- SEC Form 8-K filed by Waters Corporation
- Waters Corporation to Present at the Jefferies Global Healthcare Conference
- SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Waters Corporation